Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Observer.
Press releases published on November 3, 2025
128 Assets Ltd Appointed Agent Recruitment Partner for Cavalry Water Recycling EB-5 Project
128 Assets Ltd joins Cavalry Water Recycling as agent recruitment partner for its approved EB-5 project, combining sustainability, profit, and U.S. residency. LIVERPOOL, UNITED KINGDOM, November 3, 2025 /EINPresswire.com/ -- 128 EB-5, part of 128 Assets …
PU Prime Launches Black Friday Copy Trading Campaign
EBENE, MAURITIUS, November 3, 2025 /EINPresswire.com/ -- As the year’s busiest shopping season approaches, PU Prime, a global multi-licensed online brokerage, joins the excitement of both shoppers and investors with the launch of its Black Friday Copy …
Clinical Study Results on CercaTest RED™ Presented in 18th APCMFM
DEQING, CHINA, November 3, 2025 /EINPresswire.com/ -- Shuwen Biotech, an integrated in vitro diagnostic (IVD) company today announced that results from a prospective clinical study on CercaTest RED™ was presented in the Asia Pacific Congress in Maternal …
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designation from both FDA …
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of …
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming …
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the findings from the company’s interview study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes) were published on October 27 …
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and …
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit …
MAX Power More Than Doubles Length of Genesis Trend to 475 km
Identification of Radville Focus Area 375 km Southeast of First Well at Lawson Redraws the Genesis Map and Further Strengthens MAX Power’s Leadership in the Natural Hydrogen Sector MAX Power Saskatchewan Natural Hydrogen Documentary Video https://www. …
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 - Clinical update to focus on …
First Atlantic Nickel Phase 2X Drilling Expands Lateral Width of Awaruite Nickel Alloy Mineralization Along Sections S1 and S3 at RPM Zone Within Newly Expanded 4-Kilometer Target
GRAND FALLS-WINDSOR, Newfoundland and Labrador, Nov. 03, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to announce visual drilling results from Phase 2X holes AN-25 …
Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer
Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experience Dr Ruth McKernan FMedSci CBE, co-founder and Interim CEO, will continue as a Non-executive Director Cardiff, United Kingdom – 3 …
Tilkynning til handhafa íslenskra heimildarskírteina Staðfesting á gildistökudegi á breytingu íslenskra heimildarskírteina (IDRs) yfir í hlutdeildarskírteini (DIs)
Reykjavík, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tilkynning til handhafa íslenskra heimildarskírteina Staðfesting á gildistökudegi á breytingu íslenskra heimildarskírteina (IDRs) yfir í hlutdeildarskírteini (DIs) TORONTO, ONTARIO – 3 November 2025 – Amaroq Ltd …
Notice to holders of Icelandic Depository Receipts Confirmation of Effective Date for Conversion of Icelandic Depository Receipts (IDRs) into Depositary Interests (DIs)
Reykjavík, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Confirmation of Effective Date for Conversion of Icelandic Depository Receipts (IDRs) into Depositary Interests (DIs) …
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its …
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy …
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and …